Friday, January 27, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Industry News

Lipid Nanoparticle Delivery Technology Patent Awarded

by Global Biodefense Staff
August 9, 2016
Biodefense Industry News

Biodefense Industry NewsA new patent has been issued to Arbutus Biopharma Corporation for its proprietary lipid nanoparticle (LNP) delivery technology.

The claims of the patent broadly encompass populations of lipid particles effective for delivering nucleic acid payloads, including mRNA, and applications ranging from gene therapy to vaccines.  According to the company, the patent will likely cover all lipid particle formulations presently in the clinic for delivery of nucleic acids and many, if not all of the more advanced LNP-based products in preclinical development.

Significantly, the claims are not limited to particles having defined concentrations or relative ratios of lipid components, nor are the claims limited to particular lipid component structures.

“We believe that many companies attempting to deliver nucleic acids using lipid particles will need a license to our patents and would benefit from our advanced technology and from our clinical, regulatory and manufacturing knowhow,” said Dr. Mark J. Murray, Arbutus’ President and CEO. “Prospective LNP partnerships have the potential to enable the promising field of mRNA therapeutics and provide significant non-dilutive capital to extend the runway for our main mission to develop curative treatment regimens for HBV.”

Arbutus Biopharma was formerly known as Tekmira Pharmaceuticals, with a lead Ebola Virus Disease vaccine candidate, TKM-Ebola. When the Tekmira vaccine failed to perform well in a clinical trial in West Africa, the company reorganized in August 2015, changed its name, and turned its focus to hepatitis B and LNP delivery technology.

Tags: Nanotech

Related Posts

DARPA Selects Teams to Develop Vaccine Durability Prediction Model
Medical Countermeasures

DARPA Selects Teams to Develop Vaccine Durability Prediction Model

January 13, 2023
small glass vials on an assembly line await filling of vaccine solution
Industry News

Sabin Vaccine Institute to Advance Ebola Sudan and Marburg Vaccines with New BARDA Funding

January 12, 2023
How Are Bivalent COVID Vaccines Stacking Up Against Omicron?
Infectious Diseases

How Are Bivalent COVID Vaccines Stacking Up Against Omicron?

January 12, 2023
NISTCHO: New Living Reference Material for Producing Monoclonal Antibodies
Medical Countermeasures

NISTCHO: New Living Reference Material for Producing Monoclonal Antibodies

January 12, 2023
Load More

Latest News

Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
Biodefense Headlines – 24 January 2023

Biodefense Headlines – 24 January 2023

January 24, 2023
Biodefense Headlines – 17 January 2023

Biodefense Headlines – 17 January 2023

January 17, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC